

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Admedus Limited
ABN	35 088 221 078

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	John Daniel Seaberg
Date of last notice	28 June 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	18 December 2018
No. of securities held prior to change	a) Ordinary Shares 185,703 b) Unlisted Options 100,000 Exercise price of \$1.39 Exp 10 December 2020
Class	a) Ordinary Shares b) Unlisted Options c) Quoted Options
Number acquired	a) Ordinary Shares 700,000 b) Unlisted Options Nil c) Quoted Options 700,000 Exercise price of \$0.08 Exp 18 December 2021
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	a) Ordinary Shares \$56,000 b) Unlisted Options N/A c) Quoted Options Nil

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	a) Ordinary Shares 885,703 b) Unlisted Options 100,000 Exercise price of \$1.39 Exp 10 December 2020 c) Quoted Options 700,000 Exercise price of \$0.08 Exp 18 December 2021
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Subscribed for and issued under the Rights Issue Prospectus announced on 28 November 2018

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Admedus Limited
ABN	35 088 221 078

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Wayne Geoffrey Paterson
Date of last notice	28 June 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
Date of change	18 December 2018
No. of securities held prior to change	a) Ordinary Shares 216,667 b) Unlisted Options 100,000 Exercise price of \$1.39 Exp 10 December 2020 c) Unlisted Options 1,435,630 Exercise price of \$0.37 Exp 31 December 2027
Class	a) Ordinary Shares b) Unlisted Options @ \$1.39 c) Unlisted Options @ \$0.37 d) Quoted Options
Number acquired	a) Ordinary Shares 700,000 b) Unlisted Options @ \$1.39 Nil c) Unlisted Options @ \$0.37 Nil d) Quoted Options 700,000 Exercise price of \$0.08 Exp 18 December 2021
Number disposed	Nil

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	a) Ordinary Shares \$56,000 b) Unlisted Options @ \$1.39 N/A c) Unlisted Options @ \$0.37 N/A d) Quoted Options Nil
No. of securities held after change	a) Ordinary Shares 916,667 b) Unlisted Options 100,000 Exercise price of \$1.39 Exp 10 December 2020 c) Unlisted Options 1,435,630 Exercise price of \$0.37 Exp 31 December 2027 d) Quoted Options 700,000 Exercise price of \$0.08 Exp 18 December 2021
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Subscribed for and issued under the Rights Issue Prospectus announced on 28 November 2018

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Admedus Limited
ABN	35 088 221 078

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Lishan Zhang
Date of last notice	19 December 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct – Nil Indirect – as below
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Entities that Lishan Zhang has an interest in: <ul style="list-style-type: none"> ▪ Carron Services Limited ▪ Star Bright Holding Limited ▪ Constellation Immunotherapy Limited ▪ Constellation Int'l (Group) Holdings Limited
Date of change	18 December 2018
No. of securities held prior to change	<ul style="list-style-type: none"> ▪ Carron Services Limited 1,666,667 Ordinary Shares ▪ Star Bright Holding Limited 2,839,633 Ordinary Shares ▪ Constellation Immunotherapy Limited 23,455,371 Ordinary Shares ▪ Constellation Int'l (Group) Holdings Limited 42,594,498 Ordinary Shares
Class	<ul style="list-style-type: none"> ▪ Ordinary Shares ▪ Quoted Options

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>Number acquired</p>	<ul style="list-style-type: none"> ▪ Carron Services Limited: <ul style="list-style-type: none"> ○ 1,190,477 Ordinary Shares ○ Quoted Options 1,190,477 Exercise price of \$0.08 Exp 18 December 2021 ▪ Star Bright Holding Limited: <ul style="list-style-type: none"> ○ 14,528,310 Ordinary Shares ○ Quoted Options 14,528,310 Exercise price of \$0.08 Exp 18 December 2021 ▪ Constellation Immunotherapy Limited: <ul style="list-style-type: none"> ○ 16,753,837 Ordinary Shares ○ Quoted Options 16,753,837 Exercise price of \$0.08 Exp 18 December 2021 ▪ Constellation Int'l (Group) Holdings Limited: <ul style="list-style-type: none"> ○ 30,424,624 Ordinary Shares ○ Quoted Options 30,424,624 Exercise price of \$0.08 Exp 18 December 2021
<p>Number disposed</p>	<p>Nil</p>
<p>Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation</p>	<ul style="list-style-type: none"> ▪ Ordinary Shares: Carron Services Limited \$95,238; Star Bright Holding Limited \$1,162,265; Constellation Immunotherapy Limited \$1,340,307 & Constellation Int'l (Group) Holdings Limited \$2,433,971 ▪ Quoted Options: Carron Services Limited Nil; Star Bright Holding Limited Nil; Constellation Immunotherapy Limited Quoted Options Nil & Constellation Int'l (Group) Holdings Limited Options Nil

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	<ul style="list-style-type: none"> ▪ Carron Services Limited: <ul style="list-style-type: none"> ○ 2,857,144 Ordinary Shares ○ Quoted Options 1,190,477 <li style="padding-left: 40px;">Exercise price of \$0.08 Exp 18 December 2021 ▪ Star Bright Holding Limited: <ul style="list-style-type: none"> ○ 17,367,943 Ordinary Shares ○ Quoted Options 14,528,310 <li style="padding-left: 40px;">Exercise price of \$0.08 Exp 18 December 2021 ▪ Constellation Immunotherapy Limited: <ul style="list-style-type: none"> ○ 40,209,208 Ordinary Shares ○ Quoted Options 16,753,837 <li style="padding-left: 40px;">Exercise price of \$0.08 Exp 18 December 2021 ▪ Constellation Int'l (Group) Holdings Limited: <ul style="list-style-type: none"> ○ 73,019,140 Ordinary Shares ○ Quoted Options 30,424,624 <li style="padding-left: 40px;">Exercise price of \$0.08 Exp 18 December 2021
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Subscribed for and issued under the Rights Issue Prospectus announced on 28 November 2018

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Admedus Limited
ABN	35 088 221 078

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Yanheng Wu
Date of last notice	19 December 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct – Nil Indirect – as below
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Entities that Yanheng Wu has an interest in: <ul style="list-style-type: none"> ▪ Constellation Immunotherapy Limited ▪ Constellation Int'l (Group) Holdings Limited
Date of change	18 December 2018
No. of securities held prior to change	<ul style="list-style-type: none"> ▪ Constellation Immunotherapy Limited 23,455,371 Ordinary Shares ▪ Constellation Int'l (Group) Holdings Limited 42,594,498 Ordinary Shares
Class	<ul style="list-style-type: none"> ▪ Ordinary Shares ▪ Quoted Options

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>Number acquired</p>	<ul style="list-style-type: none"> ▪ Constellation Immunotherapy Limited: 16,753,837 Ordinary Shares & Quoted Options 16,753,837 Exercise price of \$0.08 Exp 18 December 2021 ▪ Constellation Int'l (Group) Holdings Limited: 30,424,624 Ordinary Shares & Quoted Options 30,424,624 Exercise price of \$0.08 Exp 18 December 2021
<p>Number disposed</p>	<p>Nil</p>
<p>Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small></p>	<ul style="list-style-type: none"> ▪ Ordinary Shares: Constellation Immunotherapy Limited \$1,340,307 & Constellation Int'l (Group) Holdings Limited \$2,433,971 ▪ Quoted Options: Constellation Immunotherapy Limited Nil & Constellation Int'l (Group) Holdings Limited Nil
<p>No. of securities held after change</p>	<ul style="list-style-type: none"> ▪ Constellation Immunotherapy Limited: 40,209,208 Ordinary Shares & Quoted Options 16,753,837 Exercise price of \$0.08 Exp 18 December 2021 ▪ Constellation Int'l (Group) Holdings Limited: 73,019,140 Ordinary Shares & Quoted Options 30,424,624 Exercise price of \$0.08 Exp 18 December 2021
<p>Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small></p>	<p>Subscribed for and issued under the Rights Issue Prospectus announced on 28 November 2018</p>

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<p>Detail of contract</p>	<p>N/A</p>
<p>Nature of interest</p>	<p>N/A</p>
<p>Name of registered holder (if issued securities)</p>	<p>N/A</p>

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.